MicroRNAs as Biomarkers of Surgical Outcome in Mesial Temporal Lobe Epilepsy: A Systematic Review

Mesial temporal lobe epilepsy is the most common type of epilepsy. For most patients suffering from TLE, the only treatment option is surgery. However, there is a high possibility of relapse. Invasive EEG as a method for predicting the outcome of surgical treatment is a very complex and invasive manipulation, so the search for outcome biomarkers is an urgent task. MicroRNAs as potential biomarkers of surgical outcome are the subject of this study. For this study, a systematic search for publications in databases such as PubMed, Springer, Web of Science, Scopus, ScienceDirect, and MDPI was carried out. The following keywords were used: temporal lobe epilepsy, microRNA, biomarkers, surgery, and outcome. Three microRNAs were studied as prognostic biomarkers of surgical outcome: miR-27a-3p, miR-328-3p, and miR-654-3p. According to the results of the study, only miR-654-3p showed a good ability to discriminate between patients with poor and good surgical outcomes. MiR-654-3p is involved in the following biological pathways: ATP-binding cassette drug transporters, glutamate transporter SLC7A11, and TP53. A specific target for miR-654-3p is GLRA2, the glycine receptor subunit. MicroRNAs, which are diagnostic biomarkers of TLE, and epileptogenesis, miR-134-5p, MiR-30a, miRs-143, etc., can be considered as potential biomarkers of surgical outcome, as they can be indicators of early and late relapses. These microRNAs are involved in the processes characteristic of epilepsy: oxidative stress and apoptosis. The study of miRNAs as potential predictive biomarkers of surgical outcome is an urgent task and should be continued. However, when studying miRNA expression profiles, it is important to take into account and note a number of factors, such as the type of sample under study, the time of sampling for the study, the type and duration of the disease, and the type of antiepileptic treatment. Without taking into account all these factors, it is impossible to assess the influence and involvement of miRNAs in epileptic processes.

[1]  D. Dmitrenko,et al.  Biomarkers of Drug Resistance in Temporal Lobe Epilepsy in Adults , 2023, Metabolites.

[2]  P. Peplow,et al.  MicroRNAs as potential biomarkers in temporal lobe epilepsy and mesial temporal lobe epilepsy , 2022, Neural regeneration research.

[3]  A. Sakamoto,et al.  MicroRNAs miR-629-3p, miR-1202 and miR-1225-5p as potential diagnostic and surgery outcome biomarkers for mesial temporal lobe epilepsy with hippocampal sclerosis. , 2022, Neuro-Chirurgie.

[4]  N. Shnayder,et al.  Expression Profile of miRs in Mesial Temporal Lobe Epilepsy: Systematic Review , 2022, International journal of molecular sciences.

[5]  M. Caligiuri,et al.  Circulating microRNAs as Potential Novel Diagnostic Biomarkers to Predict Drug Resistance in Temporal Lobe Epilepsy: A Pilot Study , 2021, International journal of molecular sciences.

[6]  N. A. Shnayder,et al.  Convulsive syndrome. Part 1 , 2021, Siberian Medical Review.

[7]  Li-Gang Huang,et al.  Plasma Exosomal MiRNAs Expression Profile in Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis: Case-Control Study and Analysis of Potential Functions , 2020, Frontiers in Molecular Neuroscience.

[8]  M. Brázdil,et al.  Epilepsy miRNA Profile Depends on the Age of Onset in Humans and Rats , 2020, Frontiers in Neuroscience.

[9]  F. Rosenow,et al.  Genome-wide microRNA profiling of plasma from three different animal models identifies biomarkers of temporal lobe epilepsy , 2020, Neurobiology of Disease.

[10]  A. Sakamoto,et al.  Expression of circulating microRNAs as predictors of diagnosis and surgical outcome in patients with mesial temporal lobe epilepsy with hippocampal sclerosis , 2020, Epilepsy Research.

[11]  A. Anderson,et al.  Divergent network properties that predict early surgical failure versus late recurrence in temporal lobe epilepsy. , 2020, Journal of neurosurgery.

[12]  Guo-Hong Chen,et al.  microRNA‐139‐5p confers sensitivity to antiepileptic drugs in refractory epilepsy by inhibition of MRP1 , 2019, CNS neuroscience & therapeutics.

[13]  A. Sakamoto,et al.  Expression of MicroRNAs miR-145, miR-181c, miR-199a and miR-1183 in the Blood and Hippocampus of Patients with Mesial Temporal Lobe Epilepsy , 2019, Journal of Molecular Neuroscience.

[14]  Hongmei Wu,et al.  The MicroRNA Expression Profiles of Human Temporal Lobe Epilepsy in HS ILAE Type 1 , 2019, Cellular and Molecular Neurobiology.

[15]  H. Hamer,et al.  Dual-center, dual-platform microRNA profiling identifies potential plasma biomarkers of adult temporal lobe epilepsy , 2018, EBioMedicine.

[16]  S. Grosso,et al.  Oxidative stress in epilepsy , 2018, Expert review of neurotherapeutics.

[17]  Li-Gang Huang,et al.  Silencing rno-miR-155-5p in rat temporal lobe epilepsy model reduces pathophysiological features and cell apoptosis by activating Sestrin-3 , 2017, Brain Research.

[18]  J. D. Mills,et al.  Systematic review and meta-analysis of differentially expressed miRNAs in experimental and human temporal lobe epilepsy , 2017, Scientific Reports.

[19]  M. Brázdil,et al.  MicroRNA and mesial temporal lobe epilepsy with hippocampal sclerosis: Whole miRNome profiling of human hippocampus , 2017, Epilepsia.

[20]  Donncha F. O’Brien,et al.  Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus , 2017, Scientific Reports.

[21]  R. Secolin,et al.  MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy , 2017, PloS one.

[22]  R. Kukreti,et al.  Effect of Oxidative Stress on ABC Transporters: Contribution to Epilepsy Pharmacoresistance , 2017, Molecules.

[23]  F. Meng,et al.  Altered microRNA profiles in plasma exosomes from mesial temporal lobe epilepsy with hippocampal sclerosis , 2016, Oncotarget.

[24]  C. Elger,et al.  Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy. , 2016, Biochemical and biophysical research communications.

[25]  Jijun Sun,et al.  Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure. , 2016, Molecular medicine reports.

[26]  C. Kufta,et al.  Preoperative prediction of temporal lobe epilepsy surgery outcome , 2016, Epilepsy Research.

[27]  Asla Pitkänen,et al.  Advances in the development of biomarkers for epilepsy , 2016, The Lancet Neurology.

[28]  L. Carmant,et al.  Seizures and epilepsy: an overview for neuroscientists. , 2015, Cold Spring Harbor perspectives in medicine.

[29]  G. Condorelli,et al.  TGFβ Triggers miR-143/145 Transfer From Smooth Muscle Cells to Endothelial Cells, Thereby Modulating Vessel Stabilization. , 2015, Circulation research.

[30]  L. Tan,et al.  Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy , 2015, Scientific Reports.

[31]  Y. Liu,et al.  Genome-wide circulating microRNA expression profiling indicates biomarkers for epilepsy , 2015, Scientific Reports.

[32]  N. Costes,et al.  Advanced [18F]FDG and [11C]flumazenil PET analysis for individual outcome prediction after temporal lobe epilepsy surgery for hippocampal sclerosis , 2014, NeuroImage: Clinical.

[33]  J. Kjems,et al.  Aberrant expression of miR‐218 and miR‐204 in human mesial temporal lobe epilepsy and hippocampal sclerosis—Convergence on axonal guidance , 2014, Epilepsia.

[34]  Lone Skov,et al.  MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. , 2014, Journal of dermatological science.

[35]  F. Cendes,et al.  Epilepsies associated with hippocampal sclerosis , 2014, Acta Neuropathologica.

[36]  Wang Zi-hao,et al.  Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction , 2014, Diagnostic Pathology.

[37]  Sandeep Mittal,et al.  Invasive electroencephalography monitoring: Indications and presurgical planning , 2014, Annals of Indian Academy of Neurology.

[38]  A. Masamune,et al.  MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. , 2014, Cellular signalling.

[39]  Lara Jehi,et al.  Temporal patterns and mechanisms of epilepsy surgery failure , 2013, Epilepsia.

[40]  C. Bielza,et al.  Machine Learning Approach for the Outcome Prediction of Temporal Lobe Epilepsy Surgery , 2013, PloS one.

[41]  S. Pradervand,et al.  Comprehensive Expression Analyses of Neural Cell-Type-Specific miRNAs Identify New Determinants of the Specification and Maintenance of Neuronal Phenotypes , 2013, The Journal of Neuroscience.

[42]  R. Stallings,et al.  Expression profiling the microRNA response to epileptic preconditioning identifies miR-184 as a modulator of seizure-induced neuronal death , 2012, Experimental Neurology.

[43]  L. Tassi,et al.  Individually tailored extratemporal epilepsy surgery in children: Anatomo-electro-clinical features and outcome predictors in a population of 53 cases , 2012, Epilepsy & Behavior.

[44]  C. E. Elger,et al.  Pediatric functional hemispherectomy: outcome in 92 patients , 2012, Acta Neurochirurgica.

[45]  Donncha F. O’Brien,et al.  Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects , 2012, Nature Medicine.

[46]  Donncha F. O’Brien,et al.  Reduced Mature MicroRNA Levels in Association with Dicer Loss in Human Temporal Lobe Epilepsy with Hippocampal Sclerosis , 2012, PloS one.

[47]  A. A. Kan,et al.  Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response , 2012, Cellular and Molecular Life Sciences.

[48]  K. Vickers,et al.  Lipid-based carriers of microRNAs and intercellular communication , 2012, Current opinion in lipidology.

[49]  R. Blair.  Temporal Lobe Epilepsy Semiology , 2012, Epilepsy research and treatment.

[50]  R. Søkilde,et al.  Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). , 2011, Blood.

[51]  I. Najm,et al.  Temporal lobe epilepsy surgery failures: predictors of seizure recurrence, yield of reevaluation, and outcome following reoperation. , 2010, Journal of neurosurgery.

[52]  Manisha N. Patel,et al.  Mitochondria, oxidative stress, and temporal lobe epilepsy , 2010, Epilepsy Research.

[53]  M. Sim,et al.  Regulation of RUNX3 Tumor Suppressor Gene Expression in Cutaneous Melanoma , 2009, Clinical Cancer Research.

[54]  H. Vinters,et al.  Incomplete resection of focal cortical dysplasia is the main predictor of poor postsurgical outcome , 2009, Neurology.

[55]  R. Zannolli,et al.  Drug-resistant epilepsy and epileptic phenotype-EEG association in MECP2 mutated Rett syndrome , 2008, Clinical Neurophysiology.

[56]  M. Pascual.  Temporal lobe epilepsy: clinical semiology and neurophysiological studies. , 2007, Seminars in ultrasound, CT, and MR.

[57]  T. Bliss,et al.  The Hippocampus Book , 2006 .

[58]  H H Morris,et al.  Predictors of outcome after temporal lobectomy for the treatment of intractable epilepsy , 2006, Neurology.

[59]  Anthony G Marson,et al.  Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial , 2006, The Lancet Neurology.

[60]  R. Simon,et al.  Epilepsy and Apoptosis Pathways , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[61]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.